Propranolol Dosing for Vestibular Migraine

Evidence-Based Dosing Strategy

The American College of Physicians-supported dosing range for migraine prophylaxis is 80-240 mg/day, with a low dose of 40 mg daily demonstrating efficacy in clinical trials while minimizing adverse effects, including fatigue, depression, nausea, dizziness, and insomnia, in patients with vestibular migraine 1, 2
The guideline-supported approach suggests starting with a low dose close to 1 mg/kg body weight daily, approximately 40-70 mg for most adults, to control severe migraine and minimize common adverse effects 1, 2

The American Heart Association recommends screening for absolute contraindications, including second or third-degree heart block, decompensated heart failure, asthma or obstructive airway disease, cardiogenic shock, and sinus node dysfunction without pacemaker, before initiating propranolol 4
Baseline cardiovascular assessment should include heart rate and blood pressure measurement, but routine ECG and echocardiogram are not required in otherwise healthy adults without cardiac concerns 4

The American College of Cardiology recommends monitoring for hypotension and bradycardia, especially during dose escalation, and common adverse effects include fatigue, bradycardia, hypotension, dizziness, and cold extremities 4, 5
These symptoms are generally well tolerated and rarely cause treatment discontinuation, with no routine vital sign monitoring required between appointments if the patient remains stable and asymptomatic 1, 2, 4

The American Academy of Neurology advises against abruptly discontinuing propranolol after chronic use, as this can precipitate rebound hypertension, tachycardia, or angina, and recommends tapering gradually over several weeks when discontinuing 4
Propranolol may mask hypoglycemia symptoms in diabetic patients, and avoiding routine combination with non-dihydropyridine calcium channel blockers is recommended due to increased risk of bradycardia and heart block 4

Treatment should continue for at least 6 months if effective before considering discontinuation, according to the American Academy of Neurology 4